
|Podcasts|December 3, 2021
Pharmacy Focus: Psychedelic Pharmacy - Episode 2
Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research.
Advertisement
In the second episode of the Psychedelic Pharmacy series, Payton Nyquvest, CEO and founder of Numinus, discussed the laboratory development and regulatory side of psychedelic research. In the interview, Nyquvest said he believes psychedelics will lead to a major shift in the mental health treatment paradigm in the next 3 to 5 years.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5








































































































































